BACKGROUND: The primary purpose of this study was to determine associations of accelerometer-assessed moderate- to vigorous-intensity physical activity (MVPA) and sedentary time with health-related quality of life (HRQoL) and physical function and well-being in colon cancer survivors. METHODS: Colon cancer survivors (N = 178) from Alberta, Canada (n = 92) and Western Australia (n = 86) completed a mailed survey that assessed HRQoL (Functional Assessment of Cancer Therapy-Colorectal), physical function and well-being (Trial Outcome Index-Colorectal), and relevant covariates. MVPA and sedentary time were assessed using the Actigraph GT3X+ accelerometer (60-second epochs) via a 7-day monitoring protocol. Average daily MVPA and sedentary time was corrected for wear time and then examined as quartiles. RESULTS: Adjusting for relevant demographic, behavioral, and clinical covariates, a significant difference in HRQoL scores emerged between quartile 1 (Q1) and Q4 (M(diff) = 11.5, P = .038). For physical function and well-being, a significant difference emerged between Q1 and Q4 (M(diff) = 9.1, P = .009). For fatigue, a significant difference emerged between Q1 and Q4 (M(diff) = 7.1, P = .05). Significant differences were also observed for between Q1 and Q3 (M(diff) = 2.4, P = .041), and Q1 and Q4 (M(diff) = 3.5, P = .002) for colorectal cancer-specific symptoms. There were no statistically significant associations of sedentary time with HRQoL, physical function and well-being, fatigue, or colorectal cancer-specific symptoms. CONCLUSIONS: Objectively measured MVPA, but not sedentary time, was associated with better HRQoL, physical function and well-being, and colorectal cancer-specific symptoms in colon cancer survivors. For MVPA, differences met or exceeded contemporary cutpoints for determining clinically important differences.
BACKGROUND: The primary purpose of this study was to determine associations of accelerometer-assessed moderate- to vigorous-intensity physical activity (MVPA) and sedentary time with health-related quality of life (HRQoL) and physical function and well-being in colon cancer survivors. METHODS:Colon cancer survivors (N = 178) from Alberta, Canada (n = 92) and Western Australia (n = 86) completed a mailed survey that assessed HRQoL (Functional Assessment of Cancer Therapy-Colorectal), physical function and well-being (Trial Outcome Index-Colorectal), and relevant covariates. MVPA and sedentary time were assessed using the Actigraph GT3X+ accelerometer (60-second epochs) via a 7-day monitoring protocol. Average daily MVPA and sedentary time was corrected for wear time and then examined as quartiles. RESULTS: Adjusting for relevant demographic, behavioral, and clinical covariates, a significant difference in HRQoL scores emerged between quartile 1 (Q1) and Q4 (M(diff) = 11.5, P = .038). For physical function and well-being, a significant difference emerged between Q1 and Q4 (M(diff) = 9.1, P = .009). For fatigue, a significant difference emerged between Q1 and Q4 (M(diff) = 7.1, P = .05). Significant differences were also observed for between Q1 and Q3 (M(diff) = 2.4, P = .041), and Q1 and Q4 (M(diff) = 3.5, P = .002) for colorectal cancer-specific symptoms. There were no statistically significant associations of sedentary time with HRQoL, physical function and well-being, fatigue, or colorectal cancer-specific symptoms. CONCLUSIONS: Objectively measured MVPA, but not sedentary time, was associated with better HRQoL, physical function and well-being, and colorectal cancer-specific symptoms in colon cancer survivors. For MVPA, differences met or exceeded contemporary cutpoints for determining clinically important differences.
Authors: Dori E Rosenberg; John Bellettiere; Paul A Gardiner; Veronica N Villarreal; Katie Crist; Jacqueline Kerr Journal: J Gerontol A Biol Sci Med Sci Date: 2015-08-13 Impact factor: 6.053
Authors: Siobhan M Phillips; Meir J Stampfer; June M Chan; Edward L Giovannucci; Stacey A Kenfield Journal: J Cancer Surviv Date: 2015-04-16 Impact factor: 4.442
Authors: Martijn J L Bours; Bernadette W A van der Linden; Renate M Winkels; Fränzel J van Duijnhoven; Floortje Mols; Eline H van Roekel; Ellen Kampman; Sandra Beijer; Matty P Weijenberg Journal: Oncologist Date: 2016-02-24
Authors: Ajay Gopalakrishna; Thomas A Longo; Joseph J Fantony; Michael R Harrison; Brant A Inman Journal: Urol Oncol Date: 2017-05-17 Impact factor: 3.498
Authors: Christelle Schofield; Robert U Newton; Paul A Cohen; Daniel A Galvão; Joanne A McVeigh; Ganendra R Mohan; Jason Tan; Stuart G Salfinger; Leon M Straker; Carolyn J Peddle-McIntyre Journal: Support Care Cancer Date: 2018-02-01 Impact factor: 3.603
Authors: Hiroko Kunitake; Marcia M Russell; Ping Zheng; Greg Yothers; Stephanie R Land; Laura Petersen; Louis Fehrenbacher; Jeffery K Giguere; D Lawrence Wickerham; Clifford Y Ko; Patricia A Ganz Journal: J Cancer Surviv Date: 2016-08-25 Impact factor: 4.442
Authors: Monica E Reyes; Yuanqing Ye; Yeling Zhou; Alexander Liang; Scott Kopetz; M Alma Rodriquez; Xifeng Wu; Michelle A T Hildebrandt Journal: Qual Life Res Date: 2016-08-04 Impact factor: 4.147